Navigation Links
Childhood Leukemia Subtype Resists Treatment
Date:1/9/2009

Those with rare gene have disease relapse often within 5 years of apparent remission

FRIDAY, Jan. 9 (HealthDay News) -- Researchers say they have identified a rare subtype of a childhood leukemia that does not respond well to treatment.

Those with the subtype of acute lymphoblastic leukemia (ALL) have a BCR-ABL1 fusion gene. In the Dutch and German genetic analysis of children recently diagnosed with ALL, those with this gene tended to have relapse of the disease, often within five years of initially appearing disease-free.

The findings were published online Jan. 9 and will appear in the February print issue of The Lancet Oncology.

Although success rates for treating and curing many childhood leukemias are high, some with certain subtypes of ALL tend to fair poorly. About a quarter have genetically unclassified strains of the disease in which relapse is frequent.

Being able to pinpoint this disease subtype could help guide treatment decisions and improve outcomes.

"These data suggest that the BCR-ABL1-like [subtype] constitutes a large subgroup with poor prognosis that is unrecognized with current diagnostic markers," study leader Monique Den Boer, of University Medical Centre in Rotterdam, said in a news release issued by the journal. "These patients should receive more intensive therapy with available drugs or with new, more targeted drugs for which the biology of the BCR-ABL1-like subtype needs further study. Improved treatment of this high-risk leukemia will have a great effect on the overall cure rate of childhood ALL."

More information

The Nemours Foundation has more about childhood leukemia.



-- Kevin McKeever



SOURCE: The Lancet, news release, Jan. 8, 2009


'/>"/>
Copyright©2009 ScoutNews,LLC.
All rights reserved  

Related medicine news :

1. Nemours Center for Childhood Cancer Research Receives Over $1 Million in Grants for Cancer Research in 2008
2. Gene abnormality found to predict childhood leukemia relapse
3. Childhood Trauma Tied to Chronic Fatigue Syndrome
4. New insight into aggressive childhood cancer
5. Family rejection of LGB children linked to poor health in early childhood
6. Childhood anxiety disorders can and should be treated, according to UT Southwestern national expert
7. Yeast mimics severity of mutations leading to fatal childhood illness
8. UCSF receives $24.4 million to fight early childhood cavities
9. Childhood Obesity May Cause Thyroid Problems
10. Antacid Medication in Pregnancy May Increase Childhood Asthma
11. More Than $2.4 Million Raised by National Halloween Promotion Partners to Help St. Jude Fight Childhood Cancer
Post Your Comments:
*Name:
*Comment:
*Email:
Related Image:
Childhood Leukemia Subtype Resists Treatment
(Date:12/9/2016)... NY (PRWEB) , ... December 09, 2016 , ... ... and Drug Dependence, Inc. (NCADD) is recommending the film Whispering Spirits ... and the District of Columbia as an education tool in the war against teen ...
(Date:12/9/2016)... ... December 09, 2016 , ... ... Pierre Hotel in New York, NY, on December 3rd, to benefit Holy Name ... attended the annual event, which raised over $1 million - the largest event ...
(Date:12/8/2016)... ... December 08, 2016 , ... ... Quality Insights beginning January 1, 2017. The name change aligns the entire ... measuring and improving health care quality. , “We are very proud of the ...
(Date:12/8/2016)... (PRWEB) , ... December 08, 2016 , ... ... pleased to announce that “Natural Language Processing–Enabled and Conventional Data Capture Methods for ... JMIR Medical Informatics . , Results of the comparative usability study demonstrate ...
(Date:12/8/2016)... ... ... With the increasing demand for dental implants, the National Association of Dental ... dentists and patients about the safety issues related to dental restorations. According to the ... is projected to reach $6.4 billion in 2018 with more than 30 million Americans ...
Breaking Medicine News(10 mins):
(Date:12/9/2016)... DIEGO , Dec. 9, 2016 aTyr Pharma, Inc. ... discovery and development of Physiocrine-based therapeutics to address severe, rare diseases, ... at the upcoming BMO Prescriptions for Success Healthcare Conference at the ... on Wednesday, December 14, 2016, at 4:20 p.m. ET. ... ...
(Date:12/9/2016)... , Dec. 9, 2016  Axovant Sciences Ltd. ... biopharmaceutical company focused on the treatment of dementia, ... from a Phase 2b trial evaluating treatment with ... compared with donepezil plus placebo in people with ... addition of intepirdine to treatment was associated with ...
(Date:12/8/2016)... , Dec. 8, 2016 Australia Glaucoma ... GlobalData,s new report, "Australia Glaucoma Surgery Devices ... on the Australia Glaucoma Surgery Devices market. The ... volume (in units) and average prices (USD) within ... report also provides company shares and distribution shares ...
Breaking Medicine Technology: